AACR 2025

A TGFβ-directed immune-modulatory vaccine induces T cell activation and drives antitumor activity by modulating the tumor microenvironment

AACR 2025

Immune modulatory therapeutic cancer vaccines against IDO1 and PD-L1 control tumor growth through target specific changes in the tumor microenvironment

ESMO 2024

IOB-022/KN-D38 Clinical Trial: SCCHN Cohort

Dr. Jonathan Riess, Professor of Medicine at UC Davis Comprehensive Cancer Center

SITC 2024

Phase 2 trial of the IO1O2-IO103 cancer vaccine plus pembrolizumab

Results from the first-line cohort of PD-L1 high metastatic non-small cell lung cancer

Dr. Jonathan Riess, Professor of Medicine at UC Davis Comprehensive Cancer Center